(688193)"SHANGHAI RENDU BIOTECHNOLOGY CO., LTD."Report for Q3 2026
Filed with SSE · Stock code 688193 · · 13 pages · Chinese
Summary by 6ix AI
The report confirms that the financial data has not been audited and includes key figures such as revenue and profit totals. The company reported significant increases in net profit attributable to shareholders compared to the same period last year. Additionally, the report highlights a decrease in research and development expenses as a percentage of revenue. Overall, the filing provides a comprehensive overview of the company's financial health and operational results for the quarter.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Shanghai Rendu Biotechnology Co., Ltd. on 6ix
Earlier from Shanghai Rendu Biotechnology
- (688193)"SHANGHAI RENDU BIOTECHNOLOGY CO., LTD."Announcement on Completion of Registration Change of the Legal Representative and Issuance of a New Business License
- (688193)"SHANGHAI RENDU BIOTECHNOLOGY CO., LTD."Announcement on Election of Employee Representative Director for the 3rd Board of Directors
- (688193)"SHANGHAI RENDU BIOTECHNOLOGY CO., LTD."Announcement on Completion of Election of New Board of Directors, Appointment of Senior Executives and Securities Affairs Representative, Designation of the Chairman to Act as the Board Secretary, and Designation of a Person to Act as the Chief Financial Officer
- Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
- Announcement on Election of New Board of Directors
Follow Shanghai Rendu Biotechnology into a list and get an email when it puts out news.
Follow Shanghai Rendu Biotechnology